Trial Profile
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Jul 2016 Planned primary completion date changed from 1 Aug 2013 to 1 Aug 2017.
- 12 Jul 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017.
- 19 Jan 2012 Planned number of patients changed from 100 to 50 as reported by ClinicalTrials.gov.